Patents by Inventor Robert E. Neal
Robert E. Neal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12599432Abstract: Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.Type: GrantFiled: October 15, 2021Date of Patent: April 14, 2026Assignee: Galvanize Therapeutics, Inc.Inventors: Seth S. Gleiman, Nicholas S. Mercer, Timothy J. O'Brien, Jonathan R. Waldstreicher, Kevin J. Taylor, Luis L. Mangual Arbelo, Robert E. Neal, William Sanford Krimsky, Quim Castellvi
-
Patent number: 12232792Abstract: The present invention relates to medical devices and methods for treating a lesion such as a vascular stenosis using non-thermal irreversible electroporation (NTIRE). Embodiments of the present invention provide a balloon catheter type NTIRE device for treating a target lesion comprising a plurality of electrodes positioned along the balloon that are electrically independent from each other so as to be individually selectable in order to more precisely treat an asymmetrical lesion in which the lesion extends only partially around the vessel.Type: GrantFiled: November 6, 2023Date of Patent: February 25, 2025Assignees: Virginia Tech Intellectual Properties, Inc., AngioDynamics, Inc.Inventors: Robert E. Neal, Paulo A. Garcia, Rafael V. Davalos, Peter Callas
-
Publication number: 20240390672Abstract: Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.Type: ApplicationFiled: January 18, 2024Publication date: November 28, 2024Applicant: Galvanize Therapeutics, Inc.Inventors: Robert E. Neal, William S. Krimsky, Seth S. Gleiman, Nicholas S. Mercer, Timothy J. O'Brien, Quim Castellvi, Johnathan R. Waldstreicher, Kevin J. Taylor, Luis L. Mangual Arbelo, Chiara Pastori, Ebtesam He Nafie, Mukta S. Wagh
-
Publication number: 20240350187Abstract: Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and/or other pulmonary diseases or disorders.Type: ApplicationFiled: April 24, 2024Publication date: October 24, 2024Applicant: Galvanize Therapeutics, Inc.Inventors: Jonathan Reuben Waldstreicher, William Sanford Krimsky, Denise M. Zarins, Robert J. Beetel, Paul Brian Friedrichs, Kevin James Taylor, Roman Turovskiy, Robert E. Neal
-
Patent number: 11974800Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.Type: GrantFiled: January 20, 2020Date of Patent: May 7, 2024Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Michael B. Sano, Rafael V. Davalos, John L Robertson, Paulo A. Garcia, Robert E. Neal
-
Publication number: 20240074804Abstract: The present invention relates to medical devices and methods for treating a lesion such as a vascular stenosis using non-thermal irreversible electroporation (NTIRE). Embodiments of the present invention provide a balloon catheter type NTIRE device for treating a target lesion comprising a plurality of electrodes positioned along the balloon that are electrically independent from each other so as to be individually selectable in order to more precisely treat an asymmetrical lesion in which the lesion extends only partially around the vessel.Type: ApplicationFiled: November 6, 2023Publication date: March 7, 2024Inventors: Robert E. Neal, Paulo A. Garcia, Rafael V. Davalos, Peter Callas
-
Publication number: 20220104875Abstract: Devices, systems and methods are provided to treat damaged, diseased, abnormal, obstructive, cancerous or undesired tissue (e.g. a tumor, a benign tumor, a malignant tumor, a cyst, or an area of diseased tissue, etc) by delivering specialized pulsed electric field (PEF) energy to target tissue areas. The energy is delivered in a manner so as to be non-thermal (i.e. below a threshold for causing thermal ablation). Consequently, when extracellular matrices present, the extracellular matrices are preserved, and the targeted tissue maintains its structural architecture including blood vessels and lymphatics. Thus, sensitive structures, such as biological lumens, blood vessels, nerves, etc, are preserved which are critical to maintaining the integrity and functionality of the tissue. The energy is delivered with the use of systems and devices advantageously designed for superior access to target tissue throughout the body, particularly in locations previously considered inaccessible to percutaneous approaches.Type: ApplicationFiled: October 15, 2021Publication date: April 7, 2022Applicant: Galary, Inc.Inventors: SETH S. GLEIMAN, NICHOLAS S. MERCER, TIMOTHY J. O'BRIEN, JONATHAN R. WALDSTREICHER, KEVIN J. TAYLOR, LUIS L. MANGUAL ARBELO, ROBERT E. NEAL, WILLIAM SANFORD KRIMSKY, QUIM CASTELLVI
-
Publication number: 20200323576Abstract: The present invention relates to medical devices and methods for treating a lesion such as a vascular stenosis using non-thermal irreversible electroporation (NTIRE). Embodiments of the present invention provide a balloon catheter type NTIRE device for treating a target lesion comprising a plurality of electrodes positioned along the balloon that are electrically independent from each other so as to be individually selectable in order to more precisely treat an asymmetrical lesion in which the lesion extends only partially around the vessel.Type: ApplicationFiled: May 4, 2020Publication date: October 15, 2020Inventors: Robert E. Neal, Paulo A. Garcia, Rafael V. Davalos, Peter Callas
-
Publication number: 20200197073Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.Type: ApplicationFiled: January 20, 2020Publication date: June 25, 2020Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
-
Patent number: 10537379Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.Type: GrantFiled: December 15, 2017Date of Patent: January 21, 2020Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
-
Publication number: 20180125565Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.Type: ApplicationFiled: December 15, 2017Publication date: May 10, 2018Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
-
Patent number: 8992517Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors.Type: GrantFiled: June 24, 2009Date of Patent: March 31, 2015Assignee: Virginia Tech Intellectual Properties Inc.Inventors: Rafael V. Davalos, Paulo A. Garcia, John H. Rossmeisl, John L. Robertson, Robert E. Neal
-
Publication number: 20130253415Abstract: The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of Irreversible Electroporation (IRE) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact. In particular, methods of administering non-thermal irreversible electroporation (IRE) in vivo are provided for the treatment of tumors located in vascularized tissues and organs. Embodiments of the invention further provide scaffolds and tissues from natural sources created using IRE ex vivo to remove cellular debris, maximize recellularization potential, and minimize foreign body immune response. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation.Type: ApplicationFiled: November 23, 2011Publication date: September 26, 2013Applicant: Virginia Tech Intellectual Properties, Inc.Inventors: Michael B. Sano, Rafael V. Davalos, John L. Robertson, Paulo A. Garcia, Robert E. Neal
-
Publication number: 20100030211Abstract: The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors.Type: ApplicationFiled: June 24, 2009Publication date: February 4, 2010Inventors: Rafael Davalos, Paulo A. Garcia, John H. Rossmeisl, John L. Robertson, Robert E. Neal